Shin Nippon Biomedical Laboratories Ltd. | Ownership
Companies that own Shin Nippon Biomedical Laboratories Ltd.
Sumitomo Mitsui Asset Management Co., Ltd.
2,022,100
4.86%
2,022,100
0.07%
08/31/2017
Invesco Asset Management (Japan) Ltd.
454,795
1.09%
-77,604
0.06%
12/21/2017
The Vanguard Group, Inc.
421,346
1.01%
400
0%
07/31/2018
Nomura Asset Management Co., Ltd.
388,997
0.93%
6,203
0%
07/31/2018
Dimensional Fund Advisors LP
278,600
0.67%
51,400
0%
04/30/2018
Daiwa Asset Management Co. Ltd.
198,998
0.48%
10,798
0%
07/31/2018
Nikko Asset Management Co., Ltd.
172,097
0.41%
-131,301
0%
08/20/2018
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
76,298
0.18%
1,701
0%
07/31/2018
Norges Bank Investment Management
51,600
0.12%
-17,203
0%
12/31/2017
Asset Management One Co., Ltd.
18,800
0.05%
1,200
0%
04/11/2018
| Address |
St. Luke's Tower, 12/F
Tokyo Tokyo 104
Japan
|
|
Employees
|
- |
| Website |
http://www.snbl.co.jp |
| Updated |
07/08/2019 |
| Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells. |
